UP!

VIVO $33.97

VIVO target price
33.97
0
0
Meridian Bioscience Inc.
Type
Public
Traded as NASDAQ: VIVO
S&P 600 Component
Industry Medical equipment and Life Science
Founded Cincinnati, Ohio (1977 (1977))
Founder Mr. William J. Motto
Headquarters Cincinnati, Ohio, United States
Area served
Worldwide
Key people

John A. Kraeutler (Chairman, [Executive Chairman of the Board])

John (Jack) P. Kenny(CEO)
Number of employees
550
Website

www.meridianbioscience.com
www.meridianbioscience.eu
www.meridianlifescience.com
www.bioline.com

magellandx.com

John A. Kraeutler (Chairman, [Executive Chairman of the Board])

www.meridianbioscience.com
www.meridianbioscience.eu
www.meridianlifescience.com
www.bioline.com

Meridian Bioscience Inc. (Meridian)(NASDAQ: VIVO) is an international producer and distributor of a range of diagnostic test kits. The company was founded in 1976 and is headquartered in Cincinnati, Ohio. The company consists of two segments including Diagnostics and Life Science. The focused markets of the company comprise gastrointestinal and upper respiratory infections, serology, parasitology and fungal disease testing. It distributes the products mainly to healthcare companies and organizations in over 60 countries. The company has received the United States Food and Drug Administration (FDA) clearance and introduced its molecular amplification assay into the market.

The company was founded by William J. Motto in 1977. At the beginning, he figured out a more efficient way to ship specimen samples to testing labs. With his ideas, he received a $500 investment and set up the business based in his home in Cincinnati. This is the original form of the company. Over years of development, his business expanded and grew into Meridian.

Its product base includes testing platform and technologies, diagnostic kits and foodborne products, such as tests for Enterohemorrhagic E. coli. The testing platform was developed by DNA amplification and enzyme-relevant technologies. The company operates its business in segments including Diagnostics (U.S. and European) and Life Science. In 2010 fiscal year, the sales of diagnostic products accounted for 81% of the total sales of the company. In the same year, the company completed the acquisition of the Bioline Group.

Q reports

Period Date Adjusted Actuals EPS GAAP EPS
Q4 2022 2022-11-10 Future report Set alerts
Q3 2022 2022-08-05 0.16 0.16
Q2 2022 2022-05-06 0.66 0.66
Q1 2022 2022-02-04 0.35 0.35
Q4 2021 2021-11-12 0.24 0.24
Q3 2021 2021-08-06 0.22 0.22
Q2 2021 2021-05-07 0.57 0.57
Q1 2021 2021-02-05 0.65 0.65
Q4 2020 2020-11-13 0.10 0.15
Q3 2020 2020-08-07 0.55 0.64

Ratings

2016-06-29 Reiterated Rating Canaccord Genuity Hold
2016-04-28 Reiterated Rating Canaccord Genuity Hold
2016-03-29 Reiterated Rating Robert W. Baird Hold $20.00
2016-03-28 Upgrade Hilliard Lyons Neutral to Buy $22.00
2016-03-28 Reiterated Rating Robert W. Baird Outperform $27.00 to $28.00
2016-03-28 Reiterated Rating Canaccord Genuity Hold $18.00 to $19.00
2016-03-21 Downgrade Hilliard Lyons Buy to Neutral
2016-02-01 Reiterated Rating Canaccord Genuity Hold $18.00
2016-01-27 Reiterated Rating William Blair Market Perform
2015-11-13 Reiterated Rating Canaccord Genuity Hold $18.00
2015-11-06 Boost Price Target Craig Hallum Buy $21.00 to $23.00
2015-09-15 Lower Price Target Craig Hallum Buy $22.00 to $21.00
2015-09-10 Lower Price Target Canaccord Genuity Hold $19.00 to $18.00
2015-08-27 Initiated Coverage Hilliard Lyons Buy $23.50
2015-07-27 Lower Price Target Canaccord Genuity Hold $20.00 to $19.00
2015-05-04 Boost Price Target Canaccord Genuity Hold $19.00 to $20.00
2015-04-26 Reiterated Rating Canaccord Genuity Hold $19.00
2015-01-26 Set Price Target Canaccord Genuity Hold $19.00
2015-01-23 Upgrade Craig Hallum Hold to Buy $19.00 to $22.00
2015-01-02 Downgrade Raymond James Market Perform to Underperform
2015-01-02 Downgrade Raymond James Financial Inc. Market Perform to Underperform
2014-11-06 Downgrade Robert W. Baird Outperform to Neutral $22.00
2014-04-25 Lower Price Target Cowen and Company $24.00 to $21.00
2012-07-27 Downgrade Canaccord Genuity Buy to Hold
2011-04-25 Upgrade Wedbush Underperform to Neutral $18 to $22
2011-03-24 Upgrade Canaccord Genuity Hold to Buy $30
2010-04-07 Initiated Wedbush Underperform $18
2009-11-13 Reiterated Caris & Company Average $21 to $20
2009-07-07 Initiated Caris & Company Average $21
2009-03-06 Initiated William Blair Mkt Perform
2008-10-14 Initiated Lazard Capital Buy $30
2008-07-21 Upgrade Hilliard Lyons Neutral to Long-term Buy
2008-05-14 Initiated Susquehanna Financial Neutral
2008-05-13 Initiated CL King Accumulate
2007-04-16 Downgrade Hilliard Lyons Long-term Buy to Neutral
2007-01-22 Reiterated Hilliard Lyons Long-term Buy $30 to $32
2016-06-29 Reiterated Rating Canaccord Genuity Hold
2016-04-28 Reiterated Rating Canaccord Genuity Hold
2016-03-29 Reiterated Rating Robert W. Baird Hold $20.00
2016-03-28 Upgrade Hilliard Lyons Neutral to Buy $22.00
2016-03-28 Reiterated Rating Robert W. Baird Outperform $27.00 to $28.00

There is presents forecasts of rating agencies and recommendations for investors about this ticker

Major Shareholders

Name Relationship Total Shares Holding stocks
KRAEUTLER JOHN A Chief Executive Officer 0.82%  (340050) VIVO /
LUEKE MELISSA Exec VP, CFO 0.39%  (161398) VIVO /
ROLIH SUSAN Sr. VP, Reg Affairs and QA 0.38%  (158589) VIVO /
BALDINI LAWRENCE Exec VP, Operations & IS 0.24%  (101354) VIVO /
MOTTO WILLIAM J Executive Chairman 0.17%  (69087) VIVO /
Calzavara Marco G. Pres & Managing Director, MBE 0.13%  (54057) VIVO /
Johnson Marviette D. VP, Human Resources 0.11%  (46670) VIVO /
Elagin Vecheslav A Sr VP, Research & Development 0.11%  (45989) VIVO /
EBERLY RICHARD Exec VP, Chief Commercial Off. 0.10%  (43348) VIVO /
Kenny John P. Chief Executive Officer 0.09%  (38000) VIVO /
Shaughnessy Michael C. EVP, Pres Meridian Global Dx 0.07%  (29000) VIVO /
Winslow Amy EVP, Pres & CEO of Magellan 0.05%  (22500) VIVO /
READY ROBERT J 0.05%  (18901) LYTS / VIVO /
PHILLIPS DAVID 0.03%  (12500) CTAS / VIVO /
Sazdanoff Catherine 0.02%  (7700) VIVO /
Ellingwood Dwight E 0.01%  (5980) VIVO /
McIlwraith John 0.01%  (4000) VIVO /